171 related articles for article (PubMed ID: 36947202)
1. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
Tatarczuch M; Waltham M; Shortt J; Polekhina G; Hawkes EA; Ho SJ; Trotman J; Brasacchio D; Co M; Li J; Ramakrishnan V; Dunne K; Opat SS; Gregory GP
Blood Adv; 2023 Jul; 7(14):3531-3539. PubMed ID: 36947202
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S; Tedeschi A; Hu B; Linton KM; McKay P; Leitch S; Coleman M; Zinzani PL; Jin J; Sun M; Sobieraj-Teague M; Browett P; Ke X; Thieblemont C; Ardeshna K; Bijou F; Walker P; Hawkes EA; Ho SJ; Zhou K; Liang Z; Xu J; Tankersley C; Delarue R; Co M; Trotman J
Blood Adv; 2023 Nov; 7(22):6801-6811. PubMed ID: 37682792
[TBL] [Abstract][Full Text] [Related]
3. Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.
Johansson P; Klein-Hitpass L; Grabellus F; Arnold G; Klapper W; Pförtner R; Dührsen U; Eckstein A; Dürig J; Küppers R
Oncotarget; 2016 Sep; 7(38):62627-62639. PubMed ID: 27566587
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
5. High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.
Vela V; Juskevicius D; Gerlach MM; Meyer P; Graber A; Cathomas G; Dirnhofer S; Tzankov A
Hematol Oncol; 2020 Aug; 38(3):284-292. PubMed ID: 32012328
[TBL] [Abstract][Full Text] [Related]
6. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.
Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH
Oncotarget; 2017 Mar; 8(10):17038-17049. PubMed ID: 28152507
[TBL] [Abstract][Full Text] [Related]
7. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S; Tedeschi A; Linton K; McKay P; Hu B; Chan H; Jin J; Sobieraj-Teague M; Zinzani PL; Coleman M; Thieblemont C; Browett P; Ke X; Sun M; Marcus R; Portell CA; Ardeshna K; Bijou F; Walker P; Hawkes EA; Mapp S; Ho SJ; Talaulikar D; Zhou KS; Co M; Li X; Zhou W; Cappellini M; Tankersley C; Huang J; Trotman J
Clin Cancer Res; 2021 Dec; 27(23):6323-6332. PubMed ID: 34526366
[TBL] [Abstract][Full Text] [Related]
8. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
9. Exome sequencing identifies recurrent
Jallades L; Baseggio L; Sujobert P; Huet S; Chabane K; Callet-Bauchu E; Verney A; Hayette S; Desvignes JP; Salgado D; Levy N; Béroud C; Felman P; Berger F; Magaud JP; Genestier L; Salles G; Traverse-Glehen A
Haematologica; 2017 Oct; 102(10):1758-1766. PubMed ID: 28751561
[TBL] [Abstract][Full Text] [Related]
10. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement.
Hyeon J; Lee B; Shin SH; Yoo HY; Kim SJ; Kim WS; Park WY; Ko YH
Mod Pathol; 2018 Sep; 31(9):1418-1428. PubMed ID: 29765142
[TBL] [Abstract][Full Text] [Related]
11. Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.
Vela V; Juskevicius D; Dirnhofer S; Menter T; Tzankov A
Virchows Arch; 2022 Feb; 480(2):403-413. PubMed ID: 34494161
[TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.
Martínez N; Almaraz C; Vaqué JP; Varela I; Derdak S; Beltran S; Mollejo M; Campos-Martin Y; Agueda L; Rinaldi A; Kwee I; Gut M; Blanc J; Oscier D; Strefford JC; Martinez-Lopez J; Salar A; Sole F; Rodriguez-Peralto JL; Diez-Tascón C; García JF; Fraga M; Sebastián E; Alvés J; Menárguez J; González-Carreró J; Casado LF; Bayes M; Bertoni F; Gut I; Piris MA
Leukemia; 2014 Jun; 28(6):1334-40. PubMed ID: 24296945
[TBL] [Abstract][Full Text] [Related]
13. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
Phillips T; Chan H; Tam CS; Tedeschi A; Johnston P; Oh SY; Opat S; Eom HS; Allewelt H; Stern JC; Tan Z; Novotny W; Huang J; Trotman J
Blood Adv; 2022 Jun; 6(11):3472-3479. PubMed ID: 35390135
[TBL] [Abstract][Full Text] [Related]
14. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
[TBL] [Abstract][Full Text] [Related]
15. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
Martinez-Lopez A; Curiel-Olmo S; Mollejo M; Cereceda L; Martinez N; Montes-Moreno S; Almaraz C; Revert JB; Piris MA
Am J Surg Pathol; 2015 May; 39(5):644-51. PubMed ID: 25723115
[TBL] [Abstract][Full Text] [Related]
16. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
[TBL] [Abstract][Full Text] [Related]
17. Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.
Peveling-Oberhag J; Wolters F; Döring C; Walter D; Sellmann L; Scholtysik R; Lucioni M; Schubach M; Paulli M; Biskup S; Zeuzem S; Küppers R; Hansmann ML
BMC Cancer; 2015 Oct; 15():773. PubMed ID: 26498442
[TBL] [Abstract][Full Text] [Related]
18. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
Hunter ZR; Xu L; Tsakmaklis N; Demos MG; Kofides A; Jimenez C; Chan GG; Chen J; Liu X; Munshi M; Gustine J; Meid K; Patterson CJ; Yang G; Dubeau T; Samur MK; Castillo JJ; Anderson KC; Munshi NC; Treon SP
Blood Adv; 2018 Nov; 2(21):2937-2946. PubMed ID: 30401751
[TBL] [Abstract][Full Text] [Related]
19. Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.
van den Brand M; Rijntjes J; Hebeda KM; Menting L; Bregitha CV; Stevens WB; van der Velden WJ; Tops BB; van Krieken JH; Groenen PJ
Histopathology; 2017 Jan; 70(2):174-184. PubMed ID: 27297871
[TBL] [Abstract][Full Text] [Related]
20. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.
Parry M; Rose-Zerilli MJ; Ljungström V; Gibson J; Wang J; Walewska R; Parker H; Parker A; Davis Z; Gardiner A; McIver-Brown N; Kalpadakis C; Xochelli A; Anagnostopoulos A; Fazi C; de Castro DG; Dearden C; Pratt G; Rosenquist R; Ashton-Key M; Forconi F; Collins A; Ghia P; Matutes E; Pangalis G; Stamatopoulos K; Oscier D; Strefford JC
Clin Cancer Res; 2015 Sep; 21(18):4174-4183. PubMed ID: 25779943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
